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DC subtype is currently unclear. Understanding 
the emerging complexities of human DC sub-
set biology is therefore essential to develop new 
vaccines and therapeutics targeting DC.
The characterization and function of hu-
man DC subsets has been confounded by their 
rarity, the lack of distinctive markers, and lim-
ited access to human tissues. Human blood DCs 
comprise 1% of circulating PBMCs and 
have been classically defined as Ag-presenting 
leukocytes that lack other leukocyte lineage 
markers (CD3, 14, 15, 19, 20, and 56) and 
express high levels of MHC class II (HLA-DR) 
molecules (Hart, 1997). These can be broadly 
categorized into two groups: plasmacytoid 
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The essential role of DCs in the induction and 
regulation of immune responses to pathogens, 
self-antigens (Ags), and cancers is now well es-
tablished. All DCs excel at processing and pre-
senting Ag and priming naive T cell responses, 
but the complexity of DC subsets and their in-
dividual specialized functions is just becoming 
apparent (MacDonald et al., 2002; Villadangos 
and Schnorrer, 2007; Naik, 2008). Promising 
DC-based therapeutic vaccines have been de-
scribed to treat malignancies and infections 
(Vulink et al., 2008), but the majority of these 
use in vitro–generated monocyte-derived DC 
(MoDC), and the physiological standing of this 
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The characterization of human dendritic cell (DC) subsets is essential for the design of new 
vaccines. We report the first detailed functional analysis of the human CD141+ DC subset. 
CD141+ DCs are found in human lymph nodes, bone marrow, tonsil, and blood, and the 
latter proved to be the best source of highly purified cells for functional analysis. They are 
characterized by high expression of toll-like receptor 3, production of IL-12p70 and IFN-, 
and superior capacity to induce T helper 1 cell responses, when compared with the more 
commonly studied CD1c+ DC subset. Polyinosine-polycytidylic acid (poly I:C)–activated 
CD141+ DCs have a superior capacity to cross-present soluble protein antigen (Ag) to CD8+ 
cytotoxic T lymphocytes than poly I:C–activated CD1c+ DCs. Importantly, CD141+ DCs, but 
not CD1c+ DCs, were endowed with the capacity to cross-present viral Ag after their uptake 
of necrotic virus-infected cells. These findings establish the CD141+ DC subset as an impor-
tant functionally distinct human DC subtype with characteristics similar to those of the 
mouse CD8+ DC subset. The data demonstrate a role for CD141+ DCs in the induction of 
cytotoxic T lymphocyte responses and suggest that they may be the most relevant targets 
for vaccination against cancers, viruses, and other pathogens.
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cells, whereas the CD1c+ DC and CD141+ DC subsets ap-
pear to have a common origin and represent two different 
stages of a similar subset (Lindstedt et al., 2005). However, 
CD1c+ and CD141+ DCs each have unique gene expres-
sion profiles distinct from monocytes and MoDC, and this 
predicts that they have different functions (Dzionek et al., 
2000; MacDonald et al., 2002; Lindstedt et al., 2005).
The concept of distinct DC subtypes with unique capabil-
ities to influence immunological outcomes is exemplified 
by the mouse CD8 and CD8+ conventional DC subsets 
that reside in the lymph nodes and spleen (Villadangos and 
Schnorrer, 2007; Naik, 2008). The CD8 DC subset appears 
to be most effective at inducing Th2 responses (Maldonado-
López et al., 1999; Pulendran et al., 1999) and processing and 
presenting Ag to CD4+ T cells via the MHC class II pathway 
(Pooley et al., 2001; Dudziak et al., 2007; Villadangos and 
Schnorrer, 2007). In contrast, the CD8+ DC subset has a 
unique ability to take up dead or dying cells and to process 
and present exogenous Ag on MHC class I molecules to 
CD8+ T cells (i.e., cross-presentation; den Haan et al., 2000; 
Iyoda et al., 2002; Schnorrer et al., 2006). There is now sub-
stantial evidence that the CD8+ DC subset plays a crucial 
role in the induction of protective CD8+ CTL responses that 
are essential for the eradication of cancers, viruses, and other 
pathogenic infections (Dudziak et al., 2007; Hildner et al., 
2008; López-Bravo and Ardavín, 2008; Naik, 2008). The 
identification of the human DC subset with similar functional 
capacity would be a significant advance and would enable 
translation of mouse DC biology into clinical practice.
Correlation of the human and 
mouse DC subsets has been hampered 
by differences in their defining markers 
(human DCs do not express CD8). 
Interestingly, computational genome-
wide expression profiling clustered 
human CD141+ DC and CD1c+ DC 
with the mouse CD8+ and CD8 
conventional DC subsets, respectively 
(Robbins et al., 2008). Human CD141+ 
DC and mouse CD8+ DC share a 
number of phenotypic similarities, 
CD11cCD123+ DC and conventional or myeloid 
CD11c+CD123 DC. We have described three further 
phenotypically distinct subsets of CD11c+ DC, defined by 
their expression of CD16, CD1c (BDCA-1), and CD141 
(BDCA-3; MacDonald et al., 2002). Gene expression pro-
filing and hierarchical clustering data has indicated that plas-
macytoid DC and CD16+ DC arise from separate precursor 
Figure 1. CD141+ DCs are located in human tonsil, bone marrow, 
and peripheral blood. DCs in human peripheral blood (PBMC), tonsil, and 
bone marrow were identified as lineageHLA-DR+ events (top), and 
CD141+CLEC9A+ cells within this population are shown (bottom). The 
percentage of total mononuclear cells that were CD141+CLEC9A+ for the 
donor illustrated was 0.05% in PBMC, 0.08% in tonsil, and 0.05% in bone 
marrow. Analysis of one of three donors for each tissue is shown.
Figure 2. CD141+ DCs are located in 
human lymph nodes. Cells expressing 
CLEC9A in human lymph nodes colonized the 
paracortex beneath the capsule and trabecu-
lae (A–C), the more central areas of the CD3+ 
T cell rich paracortex (D–H), and the diffuse 
paracortex that protrudes between the med-
ullary cords (I–K). Co-staining with CD209 
demonstrated that neither the CD209+ anti-
gen-presenting cells in the medullary cords 
nor the surrounding diffuse paracortex ex-
pressed CLEC9A (F–K). Blue represents DAPI 
staining of cell nuclei (A, D, E, I, J, and K). 
Bars: (A and F) 200 µm; (D, G, and I) 100 µm; 
(E) 50 µm; (B and C) 30 µm; (H, J, and K) 20 µm.
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including expression of Toll-like receptor (TLR) 3 (Edwards 
et al., 2003; Lindstedt et al., 2005), the novel surface mole-
cule Necl2 (nectin-like protein 2; Galibert et al., 2005), and 
the C-type lectin CLEC9A (Caminschi et al., 2008; Huysamen 
et al., 2008; Sancho et al., 2008). Thus, whether the human 
CD141+ DC subset is the human functional equivalent of the 
mouse CD8+ DC subset has now become a major question 
for immunologists.
CD141+ DCs constitute only 0.03% of human PBMCs 
and, although present in other human tissues, their low pro-
portions and difficulties with aseptic human tissue access mean 
that they have never been isolated in sufficient quantity to 
study their function until now. We report the first detailed 
functional analysis of human CD141+ DCs in response to 
TLR3 stimuli and define their role in the induction of Th1 
responses and cross-presentation.
RESULTS
CD141+ DCs reside in blood and lymphoid tissues
The C-type lectin CLEC9A is selectively expressed by human 
CD141+ DC (Caminschi et al., 2008; Huysamen et al., 2008; 
Sancho et al., 2008). We confirmed CLEC9A expression on 
blood CD141+ DC and identified CD141+CLEC9A+ cells in 
human tonsils and bone marrow (Fig. 1). The CD141+CLEC9A+ 
DC comprised from 0.03 to 0.08% of the total mononuclear 
cells in these tissues. We then stained human lymph nodes and 
identified CLEC9A+ cells with morphology suggestive of DC 
(Fig. 2, A–E). These cells were distributed throughout the CD3+ 
T cell–rich paracortex (Fig. 2, A–H), including the diffuse 
T cell areas adjacent to the medullary cords (Fig. 2, F and I–K). 
CD209 defines a population of lymph node–resident Ag-
presenting cells that colonizes the medullary cords and para-
cortex (Angel et al., 2009) but is not expressed by blood DC 
(MacDonald et al., 2002). Co-staining with CLEC9A and 
CD209 antibody (Ab) showed that all the CLEC9A+ cells were 
CD209 and, although occasional CLEC9A+ cells were pres-
ent in the medullary cords, the vast majority of CLEC9A+ cells 
were restricted to paracortical areas (Fig. 2, F–K). Thus, 
CLEC9A+ DCs represent a lymph node paracortical DC pop-
ulation that is distinct from the CD209+ population.
Figure 3. Isolation of CD141+ DC and 
CD1c+ DC from apheresis products.  
(A) CD141+ DCs were enriched by an initial 
immunomagnetic depletion of lin+ cells and 
sorted as CD141bright linCD1cCD15CD16. 
(B) CD1c+ DCs were first enriched using a 
BDCA-1 immunomagnetic selection kit and 
further purified by flow cytometry sorting to 
remove residual contaminating cells. Mor-
phology of purified DC is shown at 100× 
magnification. Bars, 10 µm.
Figure 4. CD141+ DCs express high levels of TLR3. (A) TLR1-10 
mRNA expression by purified CD141+ DC and autologous PMBC by PCR. 
Data are representative of three donors for TLR9 and four donors for all 
other TLR, with the exception that TLR7 expression was found in one of 
four donors. Black lines indicate that intervening lanes have been spliced 
out. (B) TLR3 expression on human myeloid DC subsets determined by 
quantitative PCR relative to ubiquitin-conjugating enzyme (UCE). *, P = 0.03; 
**, P = 0.02; ***, P = 0.01. Symbols represent DC isolated concurrently 
from the same donor. (C) TLR3 expression by fluorescent intracellular 
staining of CD141+ DC and autologous CD1c+ DC. Top, histograms from a 
representative donor. Bottom, fold increase in mean fluorescence inten-
sity (MFI) of TLR3 over the isotype control for three donors.
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CD1c+ cells in tonsil mononuclear cells (unpublished data). 
Both subsets isolated from blood exhibited similar morphol-
ogy and phenotype to those previously described (Dzionek 
et al., 2000; MacDonald et al., 2002; Fig. 3 and not depicted). 
We also examined the transcription factors IRF8 and Batf3, 
which are essential for mouse CD8+ DC differentiation 
(Fig. S1; Schiavoni et al., 2002; Aliberti et al., 2003; Hildner 
et al., 2008). We found no differences in their expression be-
tween CD141+ DC and autologous CD1c+ DC. In mice, IRF8 
positively regulates indoleamine 2,3-dioxygenase (IDO) tran-
scription but negatively regulates TYRO protein tyrosine binding 
protein (TYROBP), which encodes signaling adapter DAP12. 
Thus, IRF8 expression is associated with a tolerogenic phe-
notype and TYROBP expression with an immunogenic phe-
notype (Orabona et al., 2006). Consistent with mouse CD8+ 
DC and human gene expression profiling data (Robbins et al., 
2008), we found that the IRF8/TYROBP mRNA ratio was 
higher in freshly isolated CD141+ DC than in autologous 
CD1c+ DC in four or five donors (Fig. S1).
To gain insight into CD141+ DC function, we first ex-
amined its TLR expression profile. CD141+ DC expressed 
CD141+ DCs express high levels of TLR3 and produce IFN- 
and IL-12p70
Because PBMCs are the most feasible source of CD141+ DC, 
we developed a protocol to isolate highly pure (>99%) 
CD141+ DC from healthy donor leukapheresis products in 
sufficient numbers for phenotypic and functional analyses. 
This procedure consisted of an initial depletion of lineage-
positive mononuclear cells by negative immunomagnetic se-
lection followed by flow cytometry sorting for CD141+ DC 
(Fig. 3 A). Consistent with their low frequency, we obtained, 
on average, 100 (± SD 45, n = 17) highly pure CD141+ DCs 
per 106 input PBMCs. CD1c+ DCs were isolated by first de-
pleting B cells and enriching for CD1c+ DCs using a com-
mercial immunomagnetic selection kit and then further 
purified by flow cytometry sorting (Fig. 3 B). Consistent 
with their higher abundance in blood, the yields of CD1c+ 
DCs were significantly higher (1,023 ± 683, mean ± SD) per 
106 input PBMCs (n = 17; P < 0.0001 by paired two-tailed 
Student’s t test compared with autologous CD141+ DCs). 
DC isolation and analysis was more challenging on tonsil 
tissue, but there was a greater percentage of CD141+ than 
Figure 5. CD141+ DCs secrete IFN-, CXCL10, and IL-12p70. (A) Expression of costimulatory molecules CD40, CD80, CD83, and CD86 by CD141+ 
DC and autologous CD1c+ DC freshly isolated (0 h) or after 24-h culture in complete medium alone (24 h) or in the presence of poly I:C (24 h PIC). Left, 
one example of three donors is shown in histograms. Right, CD141+ DCs express higher levels of costimulatory markers after activation with poly I:C 
compared with autologous CD1c+ DCs. The fold increase in the MFI over the isotype control for three donors is shown. (B) Secretion of inflammatory 
cytokines and chemokines by CD141+ DC and autologous CD1c+ DC after stimulation with poly I:C and secretion of IL-12p70 after activation with a cock-
tail of poly I:C, IFN-, TNF, IFN-, and IL-1.
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CD1c+ DC produced higher levels of 
IL-1 than CD141+ DC, whereas sim-
ilar levels of IL-6, IL-8, and TNF were 
produced by both subsets (Fig. 5 B). 
Neither subset produced detectable 
levels of IL-10 (unpublished data). 
TLR3 triggering induces the produc-
tion of IFN-, which is known to en-
hance Th1 responses and cross-priming (Schulz et al., 2005; 
Le Bon and Tough, 2008). When activated with poly I:C, 
CD141+ DC secreted substantially more IFN- protein than 
CD1c+ DC (Fig. 5 B). Neither subset produced detectable 
IFN- mRNA (unpublished data). The chemokine CXCL10 
(IP-10), which plays an important role in the generation of 
antiviral immunity (Rudd et al., 2005; Lindell et al., 2008), 
was also produced in higher levels by CD141+ DC than by 
CD1c+ DC in response to poly I:C (Fig. 5 B). IL-12p35 
mRNA expression was induced in poly I:C–activated CD141+ 
DC, but this was not enhanced by the addition of CD40L, 
and IL-12p70 protein was undetectable in the culture super-
natants (unpublished data). Autologous CD1c+ DC expressed 
minimal or no IL-12p35 mRNA or IL-12p70 protein under 
the same conditions (unpublished data). However, CD141+ 
DC, but not CD1c+ DC, did produce IL-12p70 when stim-
ulated with a cocktail of poly I:C, IFN-, TNF, IFN-, and 
IL-1 (Fig. 5 B). The significantly higher expression of 
TLR3 by CD141+ DCs and their capacity to produce 
IFN-, CXCL10, and IL-12p70 are consistent with a Th1-
inducing function.
CD141+ DCs induce superior Th1 responses compared  
with CD1c+ DCs
The ability to induce proliferation of allogeneic CD4+ T cells 
in an MLR is one of the definitive features of DC. There-
fore, we compared the ability of unstimulated and poly I:C–
activated CD141+ DC and CD1c+ DC to induce CD4+ T cell 
responses in an allogeneic MLR. Both DC subsets were power-
ful and equivalent stimulators of allogeneic CD4+ T cell pro-
liferation, regardless of their activation status (Fig. 6 A). Both 
subsets induced production of substantial levels of the Th1 
mRNA for TLR1, 2, 3, 6, 8, and 10 but lacked expression of 
TLR4, 5, 7, and 9 (Fig. 4 A). This profile was similar to that 
of CD1c+ DC, with the exception that CD1c+ DC also 
expressed TLR4, 5, and 7 (Fig. S2). Notably, TLR3 was 
expressed by both CD141+ DC and CD1c+ DC and is 
also expressed by MoDC (Fig. S2; Kadowaki et al., 2001; 
Matsumoto et al., 2003; Lindstedt et al., 2005), which con-
trasts with the selective expression of TLR3 by CD141+ DC 
which is predicted by gene expression profiling (Lindstedt 
et al., 2005; Robbins et al., 2008). To reconcile this, we 
quantitated TLR3 mRNA expression by RT-PCR in puri-
fied human myeloid DC subsets and confirmed TLR3 ex-
pression by CD141+ DC, CD1c+ DC, and MoDC but not 
CD16+ DC (Fig. 4 B). However, the relative expression of 
TLR3 mRNA was significantly higher on CD141+ DC than 
on CD1c+ DC and MoDC (Fig. 4 B), and increased TLR3 
protein expression was confirmed by intracellular staining 
(Fig. 4 C). These data demonstrate that CD141+ DCs are the 
major human DC subset expressing TLR3.
We next compared the ability of CD141+ DC and autol-
ogous CD1c+ DC to respond to the TLR3 agonist polyinosine-
polycytidylic acid (poly I:C). Poly I:C did not markedly affect 
the viability of either cell type (unpublished data). Freshly 
isolated CD141+ and CD1c+ DC expressed CD40 and CD86 
with no or low CD80 and CD83 as previously reported 
(Dzionek et al., 2000; MacDonald et al., 2002; Fig. 5 A). Over-
night incubation in culture medium alone up-regulated co-
stimulatory molecule expression on both populations, whereas 
poly I:C stimulation up-regulated costimulatory molecule ex-
pression to a greater extent on CD141+ DC than on CD1c+ DC 
(Fig. 5 A). Stimulation with poly I:C induced production of in-
flammatory cytokines by both CD141+ DC and CD1c+ DC. 
Figure 6. Poly I:C–activated CD141+ DCs 
induce superior CD4+ Th1 responses  
compared with CD1c+ DCs in an allogeneic 
MLR. (A) Allogeneic CD4+ T cell proliferation 
induced by unstimulated () or poly I:C acti-
vated (+) CD141+ DC and autologous CD1c+ 
DC, or in the absence of DC (no DC), measured 
by 3[H]-thymidine incorporation and expressed 
as counts per minute (cpm) after 6 d. (B) Cyto-
kine production in the MLR cultures after 6 d. 
One representative donor of six is shown.  
(C and D) Secretion of IFN- (C) and IL-2  
(D) in the allogeneic MLR cultures after 6 d. 
Each symbol represents DC isolated from the 
same donor in all graphs. *, P = 0.063;  
**, P = 0.031.
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cytokine IFN- by the T cell cultures (Fig. 6 B). IFN- was 
not detected in the supernatants of DC cultured alone (not 
depicted) or T cells cultured in the absence of DC (Fig. 6 C). 
CD141+ DC and CD1c+ DC also induced production of IL-2, 
whereas there was little or no production of the Th2 cytokines 
IL-4 and IL-5 and the regulatory cytokine IL-10 (Fig. 6 B). 
RORt mRNA (a measure of Th17 induction) and FoxP3 
mRNA (a measure of regulatory T cells) were undetectable 
in the cultures (unpublished data). Both subsets induced pro-
duction of IL-13 that, although commonly associated with Th2 
responses, can also be associated with high IFN-–producing 
Th1 responses in cancer and infectious diseases (Alexander 
and McFarlane, 2008; Kyte et al., 2009). Notably, CD141+ 
DC stimulated secretion of higher levels of IFN- and IL-2 
by T cells compared with CD1c+ DC that was further 
enhanced after poly I:C activation (Fig. 6, C and D). These 
data demonstrate that CD141+ DCs are strong inducers of 
Th1 responses.
CD141+ DCs process and present recombinant protein  
to CD4+ T cells
We examined whether CD141+ DC could take up, process, 
and present recombinant protein Ag to autologous CD4+ T 
cells. Freshly isolated CD1c+ DC expressed higher levels of 
mRNA encoding for Ifi30 (GILT), HLA-DMA, and Ca-
thepsin H, which are reputedly associated with MHC class 
II processing (Dudziak et al., 2007; Fig. 7 A). However, 
CD141+ DC from three out of four donors expressed 
higher levels of HLA-DR compared with CD1c+ DC ex 
vivo (Fig. 7 A), and this was only marginally up-regulated 
by both subsets after overnight culture in medium alone or 
in the presence of poly I:C (Fig. 7, A and B). Both CD141+ 
and CD1c+ DC subsets had a similar capacity to take up 
Lucifer yellow (Fig. 7 C). To assess the capacity of the DC 
subsets to process and present recombinant soluble protein 
to CD4+ T cells, we used the human CMV (HCMV) pp65 
matrix protein as a model Ag. HCMV establishes latency 
and persistency in healthy individuals that is associated in 
sero-positive donors with a high frequency of pp65-specific 
CD4+ and CD8+ T cells across multiple MHC alleles (Wills 
et al., 1996). CD141+ DC and CD1c+ DC from HCMV sero-
positive donors could process and present recombinant pp65 
to autologous CD4+ T cells with similar efficiency ex vivo 
in an IFN- production assay (Fig. 7 D).
uptake by CD141+ DC and CD1c+ DC in the absence or presence of poly I:C 
(+ PIC) after 1 h of incubation at 4 or 37°C. One example donor is shown 
in the histograms, and LY uptake by three donors comparing the fold uptake 
at 37 over 4°C is shown on the right. (D) Processing and presentation of 
HCMV pp65 protein to CD4+ T cells by unstimulated () or poly I:C–activated 
(+) DC isolated from HCMV seropositive donors, as measured by intra-
cellular IFN- production by autologous CD4+ T cells. The dotted line rep-
resents the maximum background IFN- production in the absence of 
pp65 (no Ag). One example donor is shown on the left and specific IFN- 
production (pp65-no Ag) for all three donors is shown on the right.
Figure 7. MHC class II processing and presentation of HCMV pp65 
recombinant protein. (A) CD1c+ DCs express higher mRNA levels of MHC 
class II–associated molecules Ifi30, HLA-DMA, and Cathepsin H than au-
tologous CD141+ DCs by quantitative PCR relative to ubiquitin C (UBC) in 
four donors. Surface expression of HLA-DR was measured by flow cytom-
etry and expressed as the fold increase of MFI over isotype control.  
(B) Expression of HLA-DR on CD141+ DC and autologous CD1c+ DC freshly 
isolated (0 h) or after 24-h culture in complete medium alone (24 h) or in 
the presence of poly I:C (24 h PIC) in an example donor (histograms) and 
all three donors after poly I:C activation (right). (C) Lucifer yellow (LY) 
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mRNA expression of Tap1, Tap2, and Sec61a after culture 
alone or in the presence of poly I:C, higher levels were in-
duced by CD141+ DC than by CD1c+ DC when activated 
with poly I:C (Fig. 8, B–D).
To examine the capacity of CD141+ DC to directly pres-
ent peptide Ag to CD8+ T cells, DCs from HLA-A*0201+ 
donors were pulsed with the HLA-A*0201-restricted HCMV 
pp65495-503 peptide in the absence or presence of poly I:C and 
used to stimulate a pp65495-503-specific CTL line. As suggested 
by their level of MHC class I expression, CD141+ DCs were 
effective and comparable to autologous CD1c+ DCs in their 
Poly I:C enhances CD141+ DC cross-presentation  
of recombinant pp65 protein to CD8+ T cells
We investigated the ability of CD141+ DC to stimulate 
CD8+ T cells. Both CD141+ DC and CD1c+ DC expressed 
similar levels of MHC class I on their surface that was mar-
ginally up-regulated after overnight culture in medium alone 
or with poly I:C (Fig. 8 A). We then examined the expres-
sion of MHC class I processing pathway-associated molecules 
by CD141+ DC. Freshly isolated CD141+ DC and CD1c+ 
DC expressed similar low mRNA levels of Tap1 and Tap2 
and Sec61a (Fig. 8, B–D). Although both subsets up-regulated 
Figure 8. Poly I:C stimulation of CD141+ DC enhances cross-presentation of HCMV pp65 recombinant protein. (A) Expression of MHC class I 
on CD141+ DC and autologous CD1c+ DC freshly isolated (0 h) or after 24-h culture in complete medium alone (24 h) or in the presence of poly I:C 
(24 h PIC). One representative is shown in the histograms, and MFI fold increase of MHC class I expression over the isotype control for four donors 
after activation with poly I:C is shown on the right. (B–D) Expression of Tap1 (B), Tap2 (C), and Sec61a (D) by CD141+ DC and autologous CD1c+ DC. 
One example donor is shown on the left and four donors after poly I:C activation is shown on the right. (E) Presentation of the pp65495-503 peptide  
by CD141+ DC and CD1c+ DC from HLA-A*0201+ donors to a pp65495-503-specific CD8+ T cell line. One representative donor (left) and specific IFN- 
production (pp65495-503, no peptide) from two donors (right) is shown. (F) Cross-presentation of pp65 recombinant protein by CD141+ DC and autolo-
gous CD1c+ DC. Top, uptake of pp65 protein by DC subsets from a HLA-A*0201+ HCMV sero-negative donor and processing and presentation of the 
pp65495-503 epitope to pp65495-503-specific CD8+ T cells, as measured by T cell IFN- secretion. One example donor is shown. Cross-presentation is  
proteasome dependent, as it is inhibited by lactacystin (pp65 + La, one of three experiments). Bottom, specific IFN- production (pp65-noAg) by a 
pp65495-503-specific CD8+ T cell line (using DC from HLA-A*0201+ donors; black) or CD8+ T cells (using autologous DC from HLA-A*0201 HCMV  
sero-positive donors; white) as responders. *, P = 0.047; **, P = 0.031.
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necrotic fibroblasts by HLA-A*0201+ DC. We first estab-
lished that CD141+ DC and CD1c+ DC were similar in their 
capacity to ingest material from HCMV-infected necrotic 
fibroblasts (Fig. 9, A and B). Despite this, only CD141+ DC 
cross-presented the pp65495-503 epitope after uptake of the 
HCMV-infected necrotic cells (Fig. 9 C). This demonstrated 
the specialized capacity of CD141+ DC to cross-present Ag 
from necrotic cells.
DISCUSSION
Our study is the first detailed functional analysis of the human 
CD141+ DC subset. We showed that, in contrast to human 
blood CD1c+ DC, the CD141+ DC subset expressed high 
levels of TLR3, but not TLR4, 5, or 7, and produced IFN-, 
CXCL10, and IL-12p70. Poly I:C–activated CD141+ DC 
induced superior Th1 responses to those induced by CD1c+ 
presentation of peptide Ag to CD8+ T cells, and this was not 
enhanced by poly I:C (Fig. 8 E).
Cross-presentation is the process by which acquired ex-
ogenous Ag can gain access to the MHC class I processing 
pathway of DC to elicit CD8+ CTL responses. This is en-
hanced by TLR3 triggering (Schulz et al., 2005) and IFN- 
(Le Bon and Tough, 2008). The high expression of TLR3 by 
CD141+ DCs and their ability to produce IFN- after stimu-
lation with poly I:C are consistent with a specialized role in 
cross-presentation. We therefore assessed the capacity of 
CD141+ DC to process and present HCMV pp65 recombi-
nant protein to responding CD8+ T cells. Specific processing 
and presentation of the pp65495-503 epitope, after uptake of pp65 
protein by HLA-A*0201+ DC from HCMV sero-negative 
donors, was examined by stimulation of a pp65495-503-specific 
CD8+ T cell line. HCMV sero-positive donors expressing 
different HLA alleles were also used to test processing and 
presentation of pp65 using a single ex vivo stimulation of au-
tologous CD8+ T cells. Similar findings were obtained using 
both assays (Fig. 8 F). In most donors, CD141+ DCs were 
inefficient at cross-presenting unless activated with poly I:C, 
whereas CD1c+ cross-presented even in the absence of acti-
vation (Fig. 8 F). Importantly, CD141+ DCs were more effec-
tive at cross-presentation on a per cell basis than autologous 
CD1c+ DCs after poly I:C activation (Fig. 8 F). Activation 
with LPS did not enhance the capacity of CD1c+ DC to 
cross-present compared with poly I:C or unstimulated CD1c+ 
DC (Fig. S3 C). Processing of pp65 recombinant protein by 
CD141+ DC was confirmed to be proteasome dependent, 
as it was blocked by the proteasome inhibitor lactacystin 
(Fig. 8 F). Thus, although both DC subsets could cross-
present recombinant protein, only cross-presentation by 
CD141+ DC was significantly enhanced by poly I:C.
CD141+ DCs cross-present Ag from HCMV-infected  
necrotic cells
Double stranded (ds) RNA released from dying cells and the 
dsRNA replication intermediary of many viruses are the nat-
ural ligands for TLR3 (Karikó et al., 2004; Cavassani et al., 
2008). CLEC9A also acts as a sensor of necrotic cells and reg-
ulator of cross-priming in mice (Sancho et al., 2009). The su-
perior capacity of CD141+ DCs to cross-present after TLR3 
stimulation and their selective expression of CLEC9A imply 
a specialized role for CD141+ DC in the cross-presentation of 
Ag from dead or dying cells. This would be especially relevant 
for the generation of protective CTL responses against tumors 
and viruses that infect cells other than DC. We therefore in-
vestigated the ability of CD141+ DC to take up and cross-
present Ag from HCMV-infected necrotic fibroblasts compared 
with autologous CD1c+ DC. For these experiments, the lab-
oratory HCMV AD169 strain, which does not directly infect 
blood DC (Fig. S4), was used to infect HLA-A*0201 fibro-
blasts, and secondary necrosis was induced by UV irradiation. 
This established a model in which processing and presenta-
tion of the pp65495-503 epitope from HCMV could only occur 
via cross-presentation after uptake of the HCMV-infected 
Figure 9. CD141+ DCs cross-present Ag from HCMV-infected  
necrotic fibroblasts. (A) Uptake of PKH-26–labeled HCMV-infected ne-
crotic fibroblasts (nHCMV-Fb) by DC subsets after 12 h at 4 and 37°C by 
flow cytometry from a representative donor (left) and by three donors 
(right). (B) Uptake of nHCMV-Fb by confocal microscopy at 200×. Bars,  
10 µm. (C) Cross-presentation of the pp6595-503 epitope after uptake of 
nHCMV-Fb or control uninfected Fb by CD141+ DC and CD1c+ DC subsets to a 
pp65-specific CD8+ T cell line, as assessed by IFN- secretion by the  
T cells. Left, one representative of four donors. Right, four donors, expressed 
as specific IFN- production (nHCMV-Fb-uninfected Fb for each cell type).
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CTL responses against blood stage Plasmodium (Lundie et al., 
2008). Based on their functional similarities to mouse CD8+ 
DCs in vitro, these data lend further support to the hypothesis 
that CD141+ DCs will be the major human DC subset in-
volved in the induction of CTL responses against tumors and 
many pathogens.
Despite their similarities, there are also notable differences 
between human CD141+ DCs and mouse CD8+ DCs. Un-
like human CD141+ DCs, mouse CD8+ DCs express TLR4 
and 9 and, thus, should respond differently to their ligands 
(Edwards et al., 2003). The transcription factors IRF8 and 
Batf3, which are known to be essential for mouse CD8+ 
DC differentiation (Schiavoni et al., 2002; Aliberti et al., 
2003; Hildner et al., 2008), were not selectively expressed by 
CD141+ DC. However, once differentiated, mouse CD8+ 
and CD8 DCs also express similar levels of Batf3 (Hildner 
et al., 2008), so our data does not exclude a role for these 
transcription factors in human CD141+ DC early develop-
ment. The ability to cross-present soluble protein was not 
unique to CD141+ DCs in humans, even though they were 
more efficient than CD1c+ DCs on a per cell basis after acti-
vation. This is not dissimilar to mouse DC because although 
CD8+ DCs are clearly the major subset involved in cross-
presentation, other mouse DC subsets, such as Langerhans 
cells and dermal CD103+ DC, also have cross-presenting ca-
pacity (Stoitzner et al., 2006; Bedoui et al., 2009b). In most 
donors, CD141+ DC required poly I:C activation in order to 
up-regulate MHC class I processing molecules and induce 
cross-presentation of protein Ag, whereas these features are 
characteristic of CD8+ DC, even in the absence of activa-
tion (Pooley et al., 2001; Schnorrer et al., 2006). Further 
studies will be necessary to establish whether these represent 
interspecies differences in DC function or could be explained 
by their tissue locality (human DCs are isolated from blood, 
whereas mouse DCs are generally isolated from spleen). 
Transcriptome differences between the human DC subsets 
isolated from blood and tonsil reinforces the latter possibility 
(Lindstedt et al., 2005). Blood CD141+ DCs may be a pre-
cursor of their lymphoid tissue counterparts, similar to the 
recently described mouse splenic CD8+ DC precursor pop-
ulation defined as CD8CD24+ DCs, which are phenotyp-
ically similar and cross-present but with lower efficiency than 
CD8+ DCs (Bedoui et al., 2009a). Interestingly, mouse 
CD8-CD24+ DCs are also very rare (2% of DC in mouse 
spleen) but are more effective than CD8+ DCs at inducing 
T cell responses and promoting viral clearance.
The human CD1c+ DC subset is hypothesized to be sim-
ilar to the mouse CD8 DC subset, and our data reinforces 
this further alignment of the human and mouse DC subsets 
(Robbins et al., 2008). Like human CD1c+ DCs, mouse 
CD8 DCs are poor producers of IFN- and IL-12p70 and 
are not major inducers of Th1 responses (Maldonado-López 
et al., 1999; Pulendran et al., 1999). Unlike CD1c+ DCs, 
mouse CD8 DCs preferentially induce Th2 responses 
(Maldonado-López et al., 1999; Pulendran et al., 1999). 
Mouse CD8 DCs are specialized at presenting Ag to 
DC. Although both subsets could take up, process, and pres-
ent recombinant protein to CD4+ T cells and CD8+ T cells, 
CD141+ DCs were more efficient as individual cells in cross-
presenting recombinant protein to CD8+ T cells after activa-
tion with poly I:C. Most importantly, unlike CD1c+ DC, the 
CD141+ DC subset was able to cross-present viral Ag from 
HCMV-infected necrotic fibroblasts. These data establish 
CD141+ DC and CD1c+ DC as functionally distinct subsets 
and highlight the emerging complexity and specialized roles 
of human DC subtypes. Although rare in human blood, our 
study and others showed that CD141+ DCs are also found in 
lymph nodes, tonsil, bone marrow, and spleen where they 
localize to the T cell areas (Galibert et al., 2005; Velásquez-
Lopera et al., 2008). Moreover, they are present in propor-
tions that are similar to or higher than those of CD1c+ DCs 
in tonsil and spleen (Velásquez-Lopera et al., 2008; unpub-
lished data). Collectively, these data suggest that CD141+ 
DCs are likely to be of profound importance in the induction 
of Th1 responses and CTL responses by cross-presentation.
Our data reveal remarkable functional similarities be-
tween human CD141+ DC and mouse CD8+ DC, which, 
combined with similarities in their transcriptomes (Robbins 
et al., 2008) and shared expression of CLEC9A (Caminschi 
et al., 2008; Huysamen et al., 2008; Sancho et al., 2008) and 
Necl2 (Galibert et al., 2005), supports the hypothesis that 
these subsets have related functions. Both are extremely rare 
in blood but are present in the T cell areas of lymphoid 
tissues where their functions are mediated (Shortman and 
Liu, 2002; O’Keeffe et al., 2003; Galibert et al., 2005). 
Like human CD141+ DCs, mouse CD8+ DCs express high 
levels of TLR3 (Edwards et al., 2003) and produce IFN- in 
response to poly I:C (Scheu et al., 2008). Mouse CD8+ 
DCs are renowned for their ability to produce IL-12p70 
(Reis e Sousa et al., 1997; Maldonado-López et al., 1999; 
Hochrein et al., 2001) and induce the Th1 cytokines IL-2 
and IFN- (Maldonado-López et al., 1999; Pulendran et al., 
1999; Skokos and Nussenzweig, 2007; Soares et al., 2007), 
which concurs with our human CD141+ DC data. Extend-
ing this comparison, the lack of IL-12p70 release by CD141+ 
DC in response to poly I:C and CD40L suggests this subset 
can induce Th1 responses independently of IL-12p70, as can 
mouse CD8+ DCs (Soares et al., 2007). Most importantly, 
like human CD141+ DCs, mouse CD8+ DCs have special-
ized cross-presenting capacity, particularly after taking up 
dead/dying cells or after poly I:C activation (den Haan et al., 
2000; Iyoda et al., 2002; Schulz et al., 2005; Schnorrer et al., 
2006). Their mutual expression of high levels of MHC class 
I Ag-processing molecules (Dudziak et al., 2007) and TLR3 
and CLEC9A, which both act as sensors of necrotic cells and 
regulators of cross-priming in mice (Schulz et al., 2005; 
Cavassani et al., 2008; Sancho et al., 2009), are likely to facili-
tate this process. The crucial role of mouse CD8+ DC in 
the induction of protective CTL responses in tumor and viral 
models has been confirmed in vivo (Dudziak et al., 2007; 
Hildner et al., 2008; López-Bravo and Ardavín, 2008; Naik, 
2008). CD8+ DCs also cross-present parasite Ag and mediate 
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highly attractive concept to enhance specificity and efficacy 
and improve the logistics, cost, and availability of therapeutic 
vaccines (Steinman, 2008). Monoclonal Abs against CLEC9A 
and CD205 have demonstrated efficacy in inducing potent 
antitumor and antiviral immunity by delivering Ag to mouse 
CD8+ DC in vivo (Bonifaz et al., 2004; Sancho et al., 
2008). CLEC9A and CD205 are also expressed by human 
CD141+ DC, and our data gives proposed clinical vaccina-
tion studies using these targets new impetus and may extend 
to other therapeutic strategies that regulate DC in transplan-
tation and autoimmune disease.
MATERIALS AND METHODS
Flow cytometry phenotyping. Healthy donor peripheral blood, leuka-
pheresis products, bone marrow, and tonsil were obtained with informed 
consent after approval by the Mater Health Services Human Research Ethics 
Committee. CLEC9A Abs were gifts from M. Lahoud and K. Shortman 
(Walter and Eliza Hall Institute, Melbourne, Victoria, Australia) and G. Brown 
(University of Cape Town, Observatory, South Africa). Cells were labeled with 
combinations of PE-, FITC-, and allophycocyanin (APC)-Cy7–conjugated 
mouse anti–human lineage Ab (CD3, CD19, CD20, CD34, and CD56), 
CD11c, CD40, CD80, CD83, CD86, HLA-ABC, and HLA-DR Ab, or 
isotype controls (all obtained from BD). Cell acquisition was performed on 
a flow cytometer (LSR II; BD) and analyzed using FlowJo (version 7.2.2; 
Tree Star, Inc.). For TLR3 staining, DCs were fixed and permeabilized us-
ing Fixation/Permeabilization buffers (eBioscience), according to the manu-
facturer’s instructions, before intracellular labeling with TLR3 or IgG isotype 
control Ab (eBioscience).
Immunohistochemistry staining of human lymph nodes. Lymph 
nodes that were as close as possible to normal lymph nodes were obtained 
from living donors undergoing surgery and donors postmortem, with no ab-
normality detected after a histopathology examination (provided by T. John, 
J. Browning, D. MacGregor, and J. Cebon, Ludwig Institute of Cancer Re-
search, Melbourne, Victoria, Australia). Lymph nodes were obtained from 
the axillary and inguinal fields. Patients or the next of kin gave written in-
formed consent, under protocols approved by the Austin Health Human 
Research Ethics Committee, Heidelberg, Melbourne.
Lymph nodes were embedded in Tissue Tek OCT compound (Sakura), 
snap frozen in liquid nitrogen, and sectioned using a cryostat. Sections 5-µm 
thick were fixed with ice-cold acetone and blocked with serum-free protein 
block (Dako). Fixed sections were probed with mouse monoclonal Ab 
against CLEC9A and CD209 (BD) and a rabbit polyclonal Ab detecting 
CD3 (Invitrogen). The primary Abs were detected with the correspond-
ing isotype-specific goat anti–mouse or goat anti–rabbit secondary Ab 
conjugated to a fluorochrome (Alexa Fluor 350, 488, or 555; Invitrogen). 
The specificity of each secondary Ab was confirmed using an isotype- or 
species-mismatched primary Ab. DAPI was included at 0.0005% wt/vol 
with the secondary Ab. The slides were mounted using Prolong Gold (Invi-
trogen). Sections were visualized with a fluorescent microscope (DMRE; 
Leica) equipped with UV, 470–490-µm, and 515–560-µm epi fluorescent 
filters (Leica). Images were acquired at room temperature using 5×/0.15 NA, 
10×/0.30 NA, 20×/0.50 NA, and 40×/0.7 NA Leica objectives, a digital 
camera (DC500; Leica), and analySIS FIVE software (Olympus). Images were 
processed using Portia image manipulation software (CytoCode Software).
DC isolations. PBMCs were isolated from leukapheresis products using 
Ficoll-Paque Plus density gradient centrifugation (GE Healthcare). CD141+ 
DCs were isolated by an initial immunomagnetic depletion of lineage-positive 
mononuclear cells followed by flow cytometry sorting. Briefly, PBMCs 
were labeled with a primary mouse anti–human monoclonal Ab cocktail 
containing CD3 (American Type Culture Collection), CD14, CD16, CD19, 
CD20, CD56 (all from Beckman Coulter), CD34, and CD235a (BD) in 
CD4+ T cells after chimeric Ab-mediated delivery of Ag 
(Dudziak et al., 2007). However, this may be restricted to 
certain types of Ag delivery strategies, as mouse CD8+ DCs are 
similarly efficient at presenting soluble protein, Escherichia coli–
derived Ag, dead cell Ag, and viral particles to CD4+ T cells 
(Schnorrer et al., 2006; Keller et al., 2010). Our study showed 
that CD1c+ DC and CD141+ DC had a similar capacity to 
present protein Ag to CD4+ T cells and, in this regard, the 
human subsets are similar to their mouse counterparts. Neither 
CD1c+ DCs nor CD8 DCs (Pooley et al., 2001; Schnorrer 
et al., 2006; Dudziak et al., 2007) are efficient at cross-
presenting necrotic cell Ag to CD8+ T cells, but we found that 
CD1c+ DCs cross-present soluble protein to a limited extent 
in the presence or absence of exogenous stimuli, which is 
consistent with another study (Schnurr et al., 2005). Human 
DC subsets may be specialized at cross-presenting particular 
types of Ag for different functional outcomes, such as priming 
or tolerance (Burgdorf and Kurts, 2008), and this will be an 
important area for future investigation.
The limited capacity of CD1c+ DC to produce IL-12p70 
and CXCL10 and augment Th1 responses and cross- 
presentation after poly I:C activation appears to be an intrinsic 
feature of this subset rather than a specific outcome of ineffi-
cient TLR3 stimulation. Our data and that of others suggest 
that CD1c+ DCs are similarly ineffective in this regard after 
activation with other stimuli, including TLR4, 7, and 8 ago-
nists, CD40L, and whole E. coli (Luft et al., 2002; Jefford 
et al., 2003; Piccioli et al., 2007). Selective expression of 
SIRP- (signal regulatory protein ) by mouse CD8 DC 
and human CD1c+ DC (Lindstedt et al., 2005; Lahoud et al., 
2006) may account for their lack of IFN- production after 
poly I:C activation (Dong et al., 2008). However, CD1c+ 
DCs are clearly capable of responding in other ways to poly 
I:C and, indeed, produced similar levels of IL-6, IL-8, and 
TNF and higher levels of IL-1 than CD141+ DCs after poly 
I:C stimulation. Poly I:C and dsRNA have recently been 
shown to signal through the RNA helicase RIG-1 in addition 
to TLR3 (Nakhaei et al., 2009), and signaling via this path-
way results in inflammasome activation and IL-1 production 
(Poeck et al., 2010). RIG-1 is selectively expressed by mouse 
CD8 DCs (Luber et al., 2010), and it is likely that CD1c+ 
DCs also respond to poly I:C via this alternate pathway.
The identification of the human DC subset with similar 
functions to mouse CD8+ DC will facilitate translation of 
the wealth of knowledge on mouse DC into clinical practice. 
This has clear implications for the design of new therapies to 
treat cancers and infectious diseases. Our data suggests that 
CD141+ DC will be the main human DC subset involved in 
stimulating CTL responses and the most appropriate one to 
target for therapeutic cancer, viral, and other pathogen (e.g., 
malaria) vaccines. The latter is supported by the detection of 
increased frequencies of circulating CD141+ DC, but not 
CD1c+ DC, in severe malaria (Urban et al., 2006). The cur-
rent clinical methods for manipulating human DC ex vivo 
are unlikely to be practical for CD141+ DC isolation. How-
ever, targeting Ag directly in vivo with DC-specific Ab is a 
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Allogeneic MLR. Allogeneic CD4+ T cells were isolated from PBMC by 
negative immunomagnetic selection after labeling with mouse monoclonal 
Ab to human CD8, CD14, CD16, CD19, CD34, CD56, HLA-DR, and 
CD235a, followed by goat anti–mouse IgG microbeads (Miltenyi Biotec) 
and separation using an autoMACS device. Donor-matched CD141+ DC 
and CD1c+ DC were cultured for 18 h with or without poly I:C and then 
washed and used to stimulate allogeneic CD4+ T cells at a ratio of 1:10. 
Wells containing CD4+ T cells, or poly I:C–stimulated or unstimulated DC 
alone, were included as controls. Cells were cultured for 6 d and T cell pro-
liferation was measured by 3[H]-thymidine incorporation during the last 
16 h of culture. Cytokines were measured in the culture supernatants after 
6 d using Flow Cytometric Bead Arrays (BD).
Uptake, processing, and presentation of recombinant pp65 protein. 
To examine uptake of soluble protein, DCs were incubated at 4 or 37°C in 
the absence or presence of poly I:C with 1 mg/ml Lucifer yellow CH Dipo-
tassium Salt (Sigma-Aldrich) for 1 h, washed four times in ice-cold PBS/0.5% 
FCS, and then analyzed by flow cytometry. For processing and presentation 
assays, DCs from HCMV sero-positive donors were loaded with 38.5 µg/ml 
of recombinant HCMVpp65 protein (Miltenyi Biotec) for 2 h in the absence 
or presence of poly I:C. Equivalent numbers of CD141+ DC and CD1c+ 
DC (50,000/well) were washed and incubated for 16 h with autologous 
PBMC at a 1:20 ratio. Ag-specific T cell stimulation was then assayed by in-
tracellular IFN- staining. Briefly, cultures were incubated in GolgiPlug 
(BD) for 4 h and then stained with mouse anti–human CD3-APC, CD4-
APC-Cy-7, and CD8-FITC, followed by fixing and permeabilization using 
a kit (Invitrogen) and intracellular staining with anti–IFN--PE or IgG-PE 
isotype control (BD) and analyzed by flow cytometry. The percentage of re-
sponding CD4+ or CD8+ T cells was calculated as the percentage of 
CD3+CD8CD4+IFN-+ or CD3+CD8+CD4IFN-+ events after sub-
traction of the respective IgG-PE isotype control.
To examine CD8+ T cell responses specific for the HLA-A*0201-
restricted HCMV pp65495-503 epitope, DCs from HLA-A*0201+ donors 
were cultured alone or with 10 µg/ml HCMVpp65 protein, pp65495-503 pep-
tide (NLVPMVATV; ProImmune), or irrelevant control peptide for 2 h in 
the absence or presence of poly I:C. For some experiments, DCs were cul-
tured with 10 µm lactacystin (Sigma-Aldrich) for 45 min before adding Ag. 
These conditions have been previously shown to be nontoxic to human cells 
(Schnurr et al., 2005). DCs were then washed and equivalent numbers of 
CD141+ DC and CD1c+ DC (25,000/well) exposed to a pp65495-503-specific 
CD8+ T cell line for 16 h at a 1:2 ratio. Ag-specific T cell stimulation 
was then assayed by intracellular IFN- staining as described in the pre-
vious paragraph.
Uptake and processing of HCMV-infected necrotic fibroblasts. The 
HLA-A*0201 human neonatal foreskin fibroblast cell line NFF59 was in-
fected with the HCMV AD169 strain (Arrode et al., 2000; both gifts from 
R. Khanna, Queensland Institute of Medical Research, Queensland, Austra-
lia) at a preoptimized multiplicity of infection of 3 for 24 h, which resulted 
in 65% infection (Fig. S4). Secondary necrosis was induced by UV irradia-
tion of the fibroblasts at 302 nm for 60 min, followed by culture for a further 
24 h, by which time >95% of fibroblasts stained positive for Annexin-V and 
propidium iodide (Fig. S4). Uninfected and HCMV-infected necrotic fibro-
blasts were co-cultured with DC at a 1:1 ratio for 12 h, and Ag uptake and 
cross-presentation were examined as described in the next two paragraphs.
For uptake experiments, fibroblasts were initially labeled with 10 µM 
PKH-26 (Sigma-Aldrich), according to the manufacturer’s instructions, be-
fore HCMV infection and UV irradiation. DCs were incubated at 4 or 37°C 
in the absence or presence of HCMV-infected necrotic fibroblasts for 12 h, 
stained with mouse anti–human CD11c-APC and HLA-DR-APC-Cy7 for 
analysis by flow cytometry, or stained and analyzed by confocal microscopy. 
For confocal microscopy, cells were labeled with HLA-DR-FITC, before 
being fixed with 4% paraformaldehyde and allowed to dry on microscope 
slides, and then mounted with prolong gold + DAPI (Invitrogen). Cells were 
viewed on a laser-scanning microscope (510 META; Carl Zeiss, Inc.) through a 
cold PBS supplemented with 0.5% BSA (Invitrogen) and 2 mM EDTA 
(Merck). After washing, cells were incubated with goat anti–mouse IgG 
microbeads (Miltenyi Biotec), and labeled cells were magnetically depleted 
using an autoMACS (Miltenyi Biotec). CD141+ DCs were further purified 
by labeling the lineage-negative enriched fraction with CD141-APC, 
CD304-PE (Miltenyi Biotec), CD15- (BD), CD1b/c- (Gen-Probe), and 
sheep anti–mouse- (Millipore) FITC and were sorted as CD141-
APC+FITCPE events using a FACSAria cell sorter (BD). CD1c+ DCs 
were isolated from the same PBMC by positive immunoselection using the 
BDCA-1+ DC isolation kit (Miltenyi Biotec) and were further purified by 
staining and flow cytometry sorting of CD1b/c-FITC+, lin-PE (BD), and 
CD141-APC events. These procedures routinely yielded CD141+ and 
CD1c+ DC preparations of >99% purity. CD16+ DCs were isolated with a 
similar procedure to the CD141+ DC isolations using an initial lineage de-
pletion step (excluding CD16 from the Ab cocktail), followed by flow sort-
ing of lineage-FITCCD16-PE+ events. MoDC were differentiated from 
monocytes that were isolated by CD14+ immunomagnetic selection (Miltenyi 
Biotec) and cultured for 5–6 d in complete AB medium supplemented with 
800 U/ml GM-CSF (Invitrogen) and 1,000 U/ml IL-4 (Invitrogen) as pre-
viously described (Radford et al., 2006).
Cells were maintained in complete AB medium consisting of RPMI 
1640, supplemented with 10% heat-inactivated human AB serum, 100 U/ml 
penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine, 1 mM sodium 
pyruvate, 0.1 mM nonessential amino acids, 10 mM Hepes buffer solution (all 
obtained from Invitrogen), and 50 µM 2-mercaptoethanol (Sigma-Aldrich) 
and were cultured in a 37°C, 5% CO2/air atmosphere incubator. Where in-
dicated, DCs were cultured in complete AB medium for 24 h alone or in the 
presence of 10 µg/ml LPS–free poly I:C (InvivoGen).
Quantitative RT-PCR. Total RNA was isolated from cells with the 
RNeasy Micro kit (QIAGEN). RNA was treated with DNase I to remove 
contaminating genomic DNA and subjected to cDNA synthesis using a 
(dT)17 primer (Roche) and Superscript III Reverse transcription (Invitro-
gen). PCR reactions for TLR1–8 and TLR10 were performed on a Thermo 
Cycler (MJ Research) using Taq DNA polymerase (QIAGEN) and primers 
and conditions previously described (Kadowaki et al., 2001). PCR for TLR9 
and UCE (Table S1, primer sequences) were performed under similar condi-
tions, except that the annealing temperature for TLR9 was 65°C. TLR3 
real-time PCR reactions were performed with TaqMan probes (Biosearch 
Technologies) and Platinum Quantitative PCR SuperMix-UDG (Invitro-
gen). UCE was used for normalization of cDNA input, and real-time 
PCR reactions were performed using a Rotor-Gene 3000 thermal cycler 
(QIAGEN). The thermal cycling conditions were initial denaturation of 
UDG (uracil DNA glycosylase) at 50°C for 2 min, followed by 45–50 cycles 
at 95°C for 15 s and at 60°C for 30 s.
Real-time PCR reactions for IRF8, TYROBP, BATF3, IFI30, HLA-
DMA, CTSH, TAP1, TAP2, SEC61A, and UBC were performed with Su-
perArray RT2 qPCR Primers (QIAGEN; Table S1) and RT2 SYBR Green 
qPCR master mix (QIAGEN). UBC was used for normalization of cDNA 
input, and real-time PCR reactions were performed using a Rotor-Gene 
3000 thermal cycler according to the manufacturer’s instructions: initial de-
naturation at 95°C for 10 min, followed by 45–50 cycles at 95°C for 15 s and 
at 60°C for 60 s. All real-time PCR data analysis was performed using 
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